Jingsheng Kangcheng

Jingsheng Kangcheng is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative gene therapies for ophthalmic and rare diseases. The company leverages its proprietary adeno-associated virus (AAV) vector platform to design treatments that address unmet medical needs in inherited retinal degenerations. Its lead candidate, JSKC-001, is a gene therapy targeting RPE65-mediated Leber congenital amaurosis (LCA2) and has progressed into clinical evaluation. Jingsheng Kangcheng aims to provide transformative solutions for patients with vision loss through advanced genetic engineering and translational medicine. The company is supported by prominent venture capital firms and maintains a robust R&D focus on ocular gene delivery.